\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

[1] Zhou C, et al. Presentation at ESMO Asia 2023; abstract 513 MO.<\/span><\/p> <\/td> \n <\/tr> \n

[2] RYBREVANT China Prescribing Information, March 2025.<\/span><\/p> <\/td> \n <\/tr> \n

[3] Grugan KD, et al. Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells. MAbs 2017;9(1):114-126.<\/span><\/p> <\/td> \n <\/tr> \n

[4] Moores SL, et al. A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors. Cancer Res 2016;76(13)(suppl 27216193):3942-3953.<\/span><\/p> <\/td> \n <\/tr> \n

[5] Yun J, et al. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC. Cancer Discov 2020;10(8):1194-1209.<\/span><\/p> <\/td> \n <\/tr> \n

[6] Vijayaraghavan S, et al. Amivantamab (JNJ-61186372), an Fc Enhanced EGFR\/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte\/Macrophage Trogocytosis. Mol Cancer Ther 2020;19(10):2044-2056.<\/span><\/p> <\/td> \n <\/tr> \n

[7] N. Girard, et al. 2023 ESMO, LBA 5<\/span><\/p> <\/td> \n <\/tr> \n

[8] Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024,4(1): page.<\/span><\/p> <\/td> \n <\/tr> \n

[9] World Health Organization. International Agency for Research on Cancer. China Fact Sheet. Available at: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/160-china-fact-sheet.pdf.<\/a> Accessed May 2024.<\/span><\/p> <\/td> \n <\/tr> \n

[10] World Health Organization. International Agency for Research on Cancer. All Cancers Fact Sheet. Available at: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/39-all-cancers-fact-sheet.pdf.<\/a> Accessed May 2024.<\/span><\/p> <\/td> \n <\/tr> \n

[11] Howlader N, et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD. https:\/\/seer.cancer.gov\/csr\/1975_2016\/<\/a>, based on November 2018 SEER data submission, posted to the SEER web site.<\/span><\/p> <\/td> \n <\/tr> \n

[12] Lin JJ, et al. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thorac Oncol. 2016 Apr;11(4):556-65.<\/span><\/p> <\/td> \n <\/tr> \n

[13] International Agency for Research on Cancer WHO, Globocan 2022, Janssen EGFR Forecast Model.<\/span><\/p> <\/td> \n <\/tr> \n

[14] ASCO, Tan AC, Tan DSW. Targeted Therapies for Lung Cancer Patients with Oncogenic Driver Molecular Alterations. J Clin Oncol 2022 Tan et al.<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n

<\/p> \n

\n<\/div>"]; $("#dvExtra").html(content_array[0]);})();